RxDoctor Payments Data

Andrew McGarry, MD

Neurology · Cherry Hill, NJNPI 1902818610

Payments from drug & device makers

$14,219in general payments, 2019–2025

Across 41 payments — averaging $346.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB SA$10K
  • Jazz Pharmaceuticals Inc.$4K
  • Acadia Pharmaceuticals Inc$170
  • Teva Pharmaceuticals USA, Inc.$99
  • AbbVie$64
  • Medtronic$52
  • plus $99 from 4 others
$7,833in research payments, 2019–2025

Across 13 payments — averaging $602.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Neurocrine Biosciences, Inc.$5K
  • Ipsen Innovation$2K
  • Acadia Pharmaceuticals Inc$1K

What the payments were for

  • Consulting fees$13,67596%
  • Speaking & faculty fees$130%
  • Travel & lodging$600%
  • Food & beverage$2162%
  • Education$2552%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$14,219 in reported general payments places this provider in the 75th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$48,753
Medicare patients
141
Services billed
1,137

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine12$267,712
NuplazidPimavanserin Tartrate47$247,573
RytaryCarbidopa/Levodopa83$171,393
NourianzIstradefylline46$143,529
NeuproRotigotine68$103,773
InbrijaLevodopa23$85,580
IngrezzaValbenazine Tosylate11$84,476
Tetrabenazine28$39,749
Carbidopa-LevodopaCarbidopa/Levodopa511$21,561
Ropinirole ErRopinirole Hcl86$15,767
Rasagiline Mesylate49$13,569
Droxidopa11$12,518
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone15$11,413
Carbidopa-Levodopa ErCarbidopa/Levodopa168$8,276
Carbidopa21$7,980

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$99$267,71212 claims
Acadia Pharmaceuticals IncNuplazid$170$247,57347 claims
Acorda Therapeutics, IncInbrija$13$85,58023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 521 neurology providers in New Jersey.

Other neurology in Cherry Hill

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →